Evidence map›Paper›PMID 39351798›Full record

Trial reportJournal of the Pediatric Infectious Diseases Society2024

Safety and Pharmacokinetics of Casirivimab and Imdevimab (CAS + IMD) in Pediatric Outpatients With COVID-19.

Thomas D Norton, Mazhar Thakur, Samit Ganguly, Shazia Ali, Jesse Chao, Alpana Waldron, Jing Xiao, Kenneth C Turner, John D Davis, Susan C Irvin and 19 more

Abstract readRandomized Controlled TrialClinical Trial, Phase IClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the Pediatric Infectious Diseases Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Thomas D NortonRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Mazhar ThakurRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Samit GangulyRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Shazia AliRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Jesse ChaoRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Alpana WaldronRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Jing XiaoRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Kenneth C TurnerRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
John D DavisRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Susan C IrvinRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Cynthia PanRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Dominique AtmodjoRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Andrea T HooperRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Jennifer D HamiltonRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Mohamed HusseinRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Danise SubramaniamRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Lilia Roque-GuerreroBio-Medical Research, Miami, Florida, USA.
Anita KohliArizona Liver Health, Tucson, Arizona, USA.
Eleftherios MylonakisInfectious Diseases Division, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.ORCID 0000-0002-4624-0777
Gregory P GebaRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Edward CoxRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Ned BraunsteinRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Paula DakinRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Bari KowalRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Rafia BhoreRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
A Thomas DiCioccioRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Diana HughesRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Gary A HermanRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Trial Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The safety of casirivimab + imdevimab (CAS + IMD) (anti-severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] monoclonal antibodies [mAbs]) in pediatric outpatients with coronavirus disease 2019 (COVID-19) was evaluated in a randomized phase 1/2/3 trial. Consistent with adults, CAS + IMD was generally well tolerated with low drug-induced immunogenicity rates. The findings support the development of next-generation anti-SARS-CoV-2 mAbs for at-risk pediatric patients.

Indexed as

Antibodies, Monoclonal, HumanizedCOVID-19 Drug TreatmentSARS-CoV-2AdolescentAntibodies, MonoclonalAntibodies, NeutralizingAntiviral AgentsChildChild, PreschoolCOVID-19Drug CombinationsFemaleHumansMaleOutpatientsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingAntiviral Agentscasirivimabcasirivimab and imdevimab drug combinationDrug CombinationsCOVID-19monoclonal antibodiesoutpatientspediatricstreatment

Identifiers

PMID39351798
PMCPMC11599144

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.